ELEKTA, A MEDTECH ONCOLOGY PLAY (BUY, 41% UPSIDE)
19/06/20 -"Elekta (Buy, Sweden), the world’s No.2 player (market share c.30%) in the $7.5bn oligopolistic radiation therapy oncology space, was dumped by investors in 2014-15 when issues cropped up within ..."
Pages
64
Language
English
Published on
19/06/20
You may also be interested by these reports :
22/03/24
We have included the announced 1,000-to-1 reverse stock split into our number of shares, following the effectiveness of the share consolidation and ...
22/03/24
We have maintained our assumption and the company’s plan of a €300m capital increase to be completed in 2024, but with an expected subscription price ...
21/03/24
Bastide’s half-year turnover and EBITDA both saw decent yoy growth despite heavier payroll costs, while the underlying operating margin moderately ...
18/03/24
DiaSorin’s 2023 results were in line with street expectations, however the profitability guidance miss disappointed investors. Healthy performance by ...